Duloxetine Gastrointestinal Adverse Effects and Their Management

Incidence and Comparative Risk

Nausea is the most frequent adverse effect of duloxetine, occurring in about 24% of treated patients versus 8% with placebo, representing a three‑fold increase and the leading cause of treatment discontinuation. 1
Duloxetine is associated with a higher combined incidence of nausea and vomiting compared with other serotonin‑norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs). 3
Dry mouth (xerostomia) is reported in 13% of patients on duloxetine versus 5% with placebo, reflecting an anticholinergic‑type effect typical of the SNRI class. 3
Constipation occurs in 10% of duloxetine‑treated patients compared with 4% on placebo. 9
Abdominal pain is observed in 5% of patients on duloxetine, a rate comparable to placebo. 9

Nausea incidence is dose‑dependent; initiating therapy at 30 mg once daily for the first 7 days and then titrating to the target 60 mg once daily markedly reduces the occurrence of nausea while preserving efficacy. 1
Rapid escalation to the full 60 mg dose without a titration period substantially increases the risk of nausea. 2

The “start low, go slow” titration regimen (30 mg → 60 mg) is recommended to minimize nausea and improve tolerability. 9

Approximately 63% of patients experience at least one adverse effect while on duloxetine; the majority are mild to moderate in severity. 8